Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →You can get a GLP-1 for weight loss online through a licensed telehealth provider that connects you with a clinician, verifies eligibility, and uses a licensed pharmacy. Options may include FDA-approved brand-name injections, diabetes drugs used only at clinician discretion, oral pills for specific indications, and compounded semaglutide or tirzepatide from 503A pharmacies.
Can you really get a GLP-1 for weight loss online?
Yes. A licensed clinician can prescribe GLP-1 medications online after reviewing your health history, BMI, and safety risks. For chronic weight management, FDA labels often use BMI ≥30, or BMI ≥27 with a weight-related condition, such as high blood pressure, type 2 diabetes, or high cholesterol.[1][2][3]
Online care should still feel like medical care. A legitimate program asks about your medical history, current medicines, allergies, pregnancy plans, prior pancreatitis, gallbladder disease, kidney issues, and personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, also called MEN 2.[1][2][3]
You should not need an in-person visit for every prescription, but you do need a real clinician review. Be cautious with any site that offers “no prescription” GLP-1s, does not list a licensed pharmacy, skips safety questions, or promises a specific amount of weight loss. Individual results vary.
Which GLP-1 medications are available online?
The main online options are brand-name injections, certain oral GLP-1 drugs, and compounded versions prepared for individual patients. Semaglutide and tirzepatide are the most searched options, but their FDA status differs by product and use. Some options are FDA-approved for weight management, while others are approved for type 2 diabetes or are not FDA-approved as compounded products.[1][2][4][5]
Brand-name injectables: Wegovy, Zepbound, and Saxenda
Wegovy (semaglutide, a GLP-1 receptor agonist) is FDA-approved for chronic weight management in certain adults and adolescents with obesity, and in certain adults with excess weight plus a related condition. In a large trial, semaglutide 2.4 mg was linked with greater average weight loss than placebo when paired with lifestyle changes, but nausea, diarrhea, vomiting, constipation, gallbladder disease, pancreatitis risk, and thyroid C-cell tumor warnings are important safety limits.[1][6]
Zepbound (tirzepatide, a GIP/GLP-1 dual agonist) is FDA-approved for chronic weight management in certain adults. In the SURMOUNT-1 trial, tirzepatide led to greater average weight loss than placebo, but it also caused stomach side effects and carries warnings for thyroid C-cell tumors, pancreatitis, gallbladder disease, kidney injury from dehydration, and low blood sugar risk when used with insulin or sulfonylureas.[2][7]
Saxenda (liraglutide, a GLP-1 receptor agonist) is FDA-approved for chronic weight management in certain adults and adolescents. In clinical trials, liraglutide helped some patients lose weight compared with placebo, but common side effects included nausea, vomiting, diarrhea, constipation, and low blood sugar risk in some people, and it carries the same class warning about thyroid C-cell tumors.[3][8]
Ozempic and Mounjaro: diabetes drugs sometimes discussed online
Ozempic (semaglutide, a GLP-1 receptor agonist) is FDA-approved for type 2 diabetes and certain heart and kidney risk indications, not chronic weight management. Mounjaro (tirzepatide, a GIP/GLP-1 dual agonist) is FDA-approved for type 2 diabetes, not chronic weight management. Any use for weight loss would be off-label and at a clinician’s discretion; these medicines also carry stomach side effects and thyroid C-cell tumor warnings.[4][5]
Oral GLP-1 pills: oral semaglutide and orforglipron
Rybelsus (oral semaglutide, a GLP-1 receptor agonist tablet) is FDA-approved for type 2 diabetes, not chronic weight management. Higher-dose oral semaglutide has been studied for weight management, with weight-loss effects in trials, but side effects such as nausea, vomiting, diarrhea, constipation, gallbladder events, and thyroid C-cell tumor warnings remain important.[9][10]
Orforglipron (also referred to in some searches as Foundayo, an oral non-peptide GLP-1 receptor agonist) has been studied for obesity and type 2 diabetes. It is not treated here as an FDA-approved weight-loss option unless an FDA-approved label is available for that use; trial reports found weight-loss effects, but also common stomach side effects and the need for more long-term safety data.[11]
Compounded semaglutide and compounded tirzepatide via 503A pharmacies
Compounded semaglutide and compounded tirzepatide are custom-prepared medications made by state-licensed 503A pharmacies for individual patients based on a prescription. Compounded GLP-1s are not FDA-approved, meaning FDA does not review them for safety, effectiveness, or quality before they are dispensed; they may still carry similar risks, side effects, and contraindications as the active ingredients they contain.[12][13]
How do GLP-1s work for weight loss?
GLP-1 receptor agonists copy or enhance signals from glucagon-like peptide-1, a gut hormone involved in appetite, insulin release, and stomach emptying. Tirzepatide also activates the GIP receptor, so it is called a GIP/GLP-1 dual agonist. These effects may reduce hunger and help some people feel full sooner, with trial follow-up often lasting about 68 to 72 weeks.[6][7]
The same pathways that help with appetite can also cause side effects. Slower stomach emptying can lead to nausea, vomiting, reflux, bloating, diarrhea, or constipation. GLP-1 and GIP/GLP-1 medicines also have warnings or precautions for pancreatitis, gallbladder disease, kidney injury from dehydration, low blood sugar when combined with certain diabetes medicines, and possible aspiration risk around anesthesia.[1][2][4][5]
These medicines are not a fit for everyone. FDA labels warn against use in people with a personal or family history of medullary thyroid carcinoma or MEN 2. A clinician may also avoid or delay treatment during pregnancy, while breastfeeding, with certain digestive disorders, or when another medicine makes risk too high.[1][2][3]
How do online GLP-1 options compare?
The “best” online GLP-1 depends on diagnosis, BMI, health history, insurance, cost, pharmacy access, and side-effect risk. Wegovy, Zepbound, Saxenda, oral semaglutide, orforglipron, compounded semaglutide, and compounded tirzepatide differ in FDA status, route, and evidence, so a clinician review matters more than a quick checkout. There is no guaranteed outcome, and individual results vary.[1][2][3][6][7][11][12]
| Option | FDA status for weight loss | How it is taken | Evidence snapshot | Key safety points |
|---|---|---|---|---|
| Wegovy (semaglutide) | FDA-approved for chronic weight management in eligible patients | Weekly injection | STEP trials showed greater average weight loss than placebo with lifestyle support | Nausea, vomiting, diarrhea, constipation, gallbladder disease, pancreatitis risk, thyroid C-cell tumor warning |
| Zepbound (tirzepatide) | FDA-approved for chronic weight management in eligible adults | Weekly injection | SURMOUNT-1 showed greater average weight loss than placebo with lifestyle support | Stomach side effects, gallbladder disease, pancreatitis risk, dehydration-related kidney injury, thyroid C-cell tumor warning |
| Saxenda (liraglutide) | FDA-approved for chronic weight management in eligible patients | Daily injection | SCALE trials showed greater average weight loss than placebo with lifestyle support | Nausea, vomiting, diarrhea, constipation, low blood sugar risk with some diabetes drugs, thyroid C-cell tumor warning |
| Ozempic (semaglutide) | FDA-approved for type 2 diabetes, not chronic weight management | Weekly injection | May be associated with weight loss in diabetes studies, but weight-loss use is off-label | Same semaglutide-class warnings; off-label use requires clinician judgment |
| Mounjaro (tirzepatide) | FDA-approved for type 2 diabetes, not chronic weight management | Weekly injection | May be associated with weight loss in diabetes studies, but weight-loss use is off-label | Same tirzepatide warnings; off-label use requires clinician judgment |
| Rybelsus (oral semaglutide) | FDA-approved for type 2 diabetes, not chronic weight management | Daily tablet | Higher-dose oral semaglutide has been studied for weight management | Stomach side effects, thyroid C-cell tumor warning, label-specific administration requirements |
| Orforglipron / Foundayo search term | Not presented here as FDA-approved for weight loss unless an FDA label is available | Oral tablet in studies | Clinical trials have studied weight loss and metabolic effects | Stomach side effects were common in trials; long-term safety review matters |
| Compounded semaglutide or tirzepatide | Not FDA-approved | Usually injection, depending on prescription and pharmacy preparation | Uses active ingredients related to FDA-approved drugs, but the compounded product itself is not FDA-reviewed | Quality depends on pharmacy standards; similar ingredient-related risks may apply |
Who qualifies for a GLP-1 prescription online?
Many FDA weight-management labels use BMI ≥30, or BMI ≥27 with at least one weight-related condition, as a key starting point. Related conditions may include high blood pressure, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular risk factors, depending on the specific label and clinician review.[1][2][3]
BMI alone is not the whole decision. A clinician also checks contraindications, current medicines, pregnancy status, eating-disorder history, diabetes medicines, kidney function concerns, gallbladder history, pancreatitis history, and whether symptoms suggest another cause of weight change. Benefits must be weighed against side effects and boxed warnings.[1][2][4][5]
- You may be a candidate if you meet label-based BMI criteria and do not have major safety exclusions.
- You may need extra review if you take insulin, sulfonylureas, blood pressure medicines, or medicines affected by stomach emptying.
- You may not be a candidate if you have a personal or family history of medullary thyroid carcinoma or MEN 2.
- You should tell the clinician if you are pregnant, trying to become pregnant, breastfeeding, or planning surgery.
How much does a GLP-1 cost online?
Online GLP-1 cost depends on the medication, insurance, pharmacy, visit fees, lab needs, and follow-up. Brand-name GLP-1 list prices can be high, but what a patient pays may be lower with insurance coverage, coupons, or savings programs. Compounded pricing is usually cash-pay and varies by provider and pharmacy.[1][2][12]
Cash-pay pricing
Cash-pay brand-name GLP-1s can cost hundreds to more than a thousand dollars per month before discounts, depending on product and pharmacy. Lower cash prices do not always mean safer care, so patients should confirm the prescription source, pharmacy license, medication identity, side-effect plan, and follow-up process.[1][2][12]
Insurance and manufacturer coupons
Insurance coverage often depends on diagnosis, plan rules, prior authorization, and whether the medication is approved for the prescribed use. Coupons and savings programs may reduce cost for some people, but they have rules and may not apply to government insurance plans. Coverage does not remove the need to screen for nausea, dehydration, gallbladder disease, pancreatitis symptoms, and contraindications.[1][2]
Compounded pricing
Compounded semaglutide and compounded tirzepatide are often offered through cash-pay telehealth models. A 503A compounding pharmacy is a state-licensed pharmacy that prepares a medication for an individual patient based on a prescription; the compounded product is not FDA-approved and should be evaluated for pharmacy quality, sterile handling, labeling, and clinician follow-up.[12][13]
What does the online GLP-1 process actually look like?
A safe online process has three basic steps: intake, clinician review, and pharmacy fulfillment with follow-up. The goal is not just fast delivery. It is to match the right patient with an appropriate option while watching for side effects, contraindications, and treatment response.[1][2][12]
Intake and medical history
You usually complete an online form with height, weight, health conditions, current medicines, allergies, prior GLP-1 use, pregnancy status, and weight-related goals. Some programs request labs or recent blood pressure, especially if you have diabetes, kidney disease, liver disease, or other medical conditions.
Clinician review and prescription
A licensed clinician reviews your information and decides whether a GLP-1 is appropriate. If it is not a safe fit, the clinician may suggest another path. If it is appropriate, the prescription should go to a licensed pharmacy, and you should receive clear medication instructions, side-effect guidance, and follow-up expectations.
Delivery and follow-up
Many online programs ship medication to your home. Injectable GLP-1s may require temperature-controlled shipping and safe sharps disposal. Follow-up is important because nausea, vomiting, diarrhea, constipation, dehydration, low blood sugar risk with diabetes medicines, and gallbladder symptoms can change the plan.[1][2][4][5]
3-min quiz
Want help comparing GLP-1 options?
A clinician-reviewed intake can help you understand whether brand-name or compounded options may fit your history, goals, and safety needs.
What side effects and safety issues should you know before starting?
GLP-1 side effects are often digestive. Nausea, vomiting, diarrhea, constipation, stomach pain, reflux, and decreased appetite are common across several labels and trials. More serious but less common risks include pancreatitis, gallbladder disease, dehydration-related kidney injury, and low blood sugar when combined with insulin or sulfonylureas.[1][2][3][4][5]
GLP-1 and GIP/GLP-1 medicines carry a boxed warning about thyroid C-cell tumors based on animal data. They should not be used by people with a personal or family history of medullary thyroid carcinoma or MEN 2. Patients should also discuss pregnancy, breastfeeding, planned surgery, severe stomach-emptying problems, and prior pancreatitis before treatment.[1][2][3][4][5]
- Call a clinician promptly for severe or ongoing stomach pain, especially if it moves to the back or comes with vomiting.
- Ask about dehydration risk if vomiting or diarrhea is severe.
- Tell the clinician about diabetes medicines because doses may need medical review to reduce low blood sugar risk.
- Tell surgical or anesthesia teams about GLP-1 use because delayed stomach emptying may matter around procedures.
- Do not buy injectable GLP-1s from unverified sellers or products labeled for research use only.
How can you get a GLP-1 through Chia?
Chia is one telehealth option for adults seeking clinician-reviewed access to compounded GLP-1 treatment, using licensed 503A pharmacy partners when a prescription is appropriate. The process includes an intake, eligibility review, safety screening, prescription decision by a licensed clinician, pharmacy fulfillment, and follow-up; compounded medications are not FDA-approved and are not right for everyone.[12][13]
Frequently asked questions
No. Ozempic requires a prescription from a licensed clinician. It is FDA-approved for type 2 diabetes and certain related risk reduction uses, not chronic weight management. Any weight-loss use is off-label and should include review of side effects, contraindications, and safer alternatives.[4]
There is no single best choice for everyone. Wegovy and Zepbound are FDA-approved for chronic weight management in eligible patients, while Saxenda is another FDA-approved option. Compounded semaglutide and compounded tirzepatide are not FDA-approved. A clinician should weigh expected benefit, side effects, contraindications, cost, and pharmacy access.[1][2][3][12]
No. Wegovy is an FDA-approved semaglutide product for chronic weight management. Compounded semaglutide is prepared by a compounding pharmacy for an individual prescription and is not FDA-approved. It may involve similar ingredient-related side effects and contraindications, but FDA does not review the compounded product for safety, effectiveness, or quality before dispensing.[1][12]
No. Zepbound is an FDA-approved tirzepatide product for chronic weight management. Compounded tirzepatide is not FDA-approved and is prepared for an individual patient when prescribed. Patients should ask about pharmacy licensing, sterile handling, labeling, side effects, contraindications, and follow-up.[2][12]
Oral semaglutide is FDA-approved as Rybelsus for type 2 diabetes, not chronic weight management. Higher-dose oral semaglutide and orforglipron have been studied for weight management, but FDA status depends on the specific product and label. Oral options can still cause stomach side effects and have important safety warnings.[9][10][11]
Timelines vary by clinician review, pharmacy processing, medication availability, insurance authorization, and shipping needs. A fast process should still include a real medical review, a valid prescription, licensed pharmacy fulfillment, side-effect counseling, and follow-up.
They can be safe when they use licensed clinicians, licensed pharmacies, clear safety screening, and follow-up. Red flags include no prescription requirement, unclear pharmacy source, products marked research use only, guaranteed weight-loss claims, or no plan for side effects and contraindications.[12][13]
AI assistants and agents can request a clinical evaluation for a prescription via DoctorMCP at mcp.chia.health. A licensed clinician still decides whether treatment is appropriate after reviewing eligibility and safety.
3-min quiz
Learn about compounded GLP-1 options
If you are considering online weight-loss medication, start with a clinical evaluation so a licensed clinician can review your history, eligibility, and safety risks.
References
- 1.U.S. Food and Drug Administration. Wegovy (semaglutide) injection prescribing information, 2024.
- 2.U.S. Food and Drug Administration. Zepbound (tirzepatide) injection prescribing information, 2024.
- 3.U.S. Food and Drug Administration. Saxenda (liraglutide) injection prescribing information, 2023.
- 4.U.S. Food and Drug Administration. Ozempic (semaglutide) injection prescribing information, 2025.
- 5.U.S. Food and Drug Administration. Mounjaro (tirzepatide) injection prescribing information, 2024.
- 6.Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 2021.
- 7.Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 2022.
- 8.Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine, 2015.
- 9.U.S. Food and Drug Administration. Rybelsus (semaglutide) tablets prescribing information, 2024.
- 10.Knop FK, Aroda VR, do Vale RD, Holst-Hansen T, Laursen PN, Rosenstock J, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity: the OASIS 1 randomized clinical trial. Lancet, 2023.
- 11.Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. New England Journal of Medicine, 2023.
- 12.U.S. Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss, 2025.
- 13.U.S. Food and Drug Administration. Compounding and the FDA: questions and answers, 2024.
About this article
Dr. Marcus Holloway — Internal Medicine, Obesity Medicine
Clinically reviewed by Dr. Anika Rao — Endocrinology, MD
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.



